Barclays

Barclays’s ARS Pharmaceuticals SPRY Stock Holding History

Barclays’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$676K	Sell	84,169 -112,218	-57%	-$1.08M	﹤0.01%	2997
2025 Q4	$2.29M	Sell	196,387 -32,182	-14%	-$313K	﹤0.01%	2846
2025 Q3	$2.3M	Sell	228,569 -393,666	-63%	-$5.65M	﹤0.01%	2789
2025 Q2	$10.9M	Buy	622,235 +490,200	+371%	+$7.07M	﹤0.01%	1523
2025 Q1	$1.66M	Sell	132,035 -26,145	-17%	-$315K	﹤0.01%	2771
2024 Q4	$1.67M	Buy	158,180 +46,514	+42%	+$651K	﹤0.01%	3039
2024 Q3	$1.62M	Buy	111,666 +73,127	+190%	+$870K	﹤0.01%	3025
2024 Q2	$328K	Buy	38,539 +8,666	+29%	+$76.9K	﹤0.01%	3295
2024 Q1	$305K	Sell	29,873 -10,501	-26%	-$78.3K	﹤0.01%	3890
2023 Q4	$221K	Buy	40,374 +22,597	+127%	+$99K	﹤0.01%	4372
2023 Q3	$67.2K	Sell	17,777 -2,683	-13%	-$17.6K	﹤0.01%	3737
2023 Q2	$137K	Sell	20,460 -15,322	-43%	-$102K	﹤0.01%	3423
2023 Q1	$233K	Buy	35,782 +14,972	+72%	+$115K	﹤0.01%	3701
2022 Q4	$178K	Buy	20,810 +825	+4%	+$5.35K	﹤0.01%	3902
2022 Q3	$106K	Sell	19,985 -912	-4%	-$4.49K	﹤0.01%	3524
2022 Q2	$89K	Buy	20,897 +3,792	+22%	+$13.2K	﹤0.01%	3820
2022 Q1	$60K	Buy	+17,105	New	+$74.5K	﹤0.01%	4041

Other funds holding SPRY

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return